- Home
- DV vs IBRX Comparison
DV vs IBRX Comparison
Compare DV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- IBRX
- Stock Information
- Founded
- DV 2008
- IBRX 2014
- Country
- DV United States
- IBRX United States
- Employees
- DV N/A
- IBRX N/A
- Industry
- DV Computer Software: Prepackaged Software
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DV Technology
- IBRX Health Care
- Exchange
- DV Nasdaq
- IBRX Nasdaq
- Market Cap
- DV 2.4B
- IBRX 2.3B
- IPO Year
- DV 2021
- IBRX N/A
- Fundamental
- Price
- DV $15.71
- IBRX $2.86
- Analyst Decision
- DV Buy
- IBRX Strong Buy
- Analyst Count
- DV 18
- IBRX 5
- Target Price
- DV $18.92
- IBRX $11.40
- AVG Volume (30 Days)
- DV 1.9M
- IBRX 7.4M
- Earning Date
- DV 08-05-2025
- IBRX 08-11-2025
- Dividend Yield
- DV N/A
- IBRX N/A
- EPS Growth
- DV N/A
- IBRX N/A
- EPS
- DV 0.29
- IBRX N/A
- Revenue
- DV $681,128,000.00
- IBRX $31,222,000.00
- Revenue This Year
- DV $16.02
- IBRX $567.98
- Revenue Next Year
- DV $11.68
- IBRX $160.56
- P/E Ratio
- DV $53.81
- IBRX N/A
- Revenue Growth
- DV 15.30
- IBRX 10238.41
- 52 Week Low
- DV $11.52
- IBRX $1.83
- 52 Week High
- DV $23.11
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- DV 61.76
- IBRX 52.22
- Support Level
- DV $15.49
- IBRX $2.64
- Resistance Level
- DV $15.87
- IBRX $2.94
- Average True Range (ATR)
- DV 0.41
- IBRX 0.17
- MACD
- DV 0.01
- IBRX 0.02
- Stochastic Oscillator
- DV 77.89
- IBRX 46.81
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.